NASDAQ
53.01USD
0.00 (0.00%)
We have scored 64 news catalysts on Soleno Therapeutics, Inc. (SLNO) over the past 12 months. The biggest single-day move next to one of them came Apr 1, 2026, when SLNO closed +10.5%: “SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit”. Coverage across the window leans negative (average ticker sentiment −0.73). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Suppliers, customers, partners and competitors of Soleno Therapeutics, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for SLNO: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market cap
2.8B
P/E
—
EPS
—
Beta
-2.22
52W range
29.43-90.3199
Day range
52.98–53.01
Open
52.99
Prev close
53.01
Volume
5M
Avg volume
3.4M
Dividend
0.00
IPO
2014-11-13
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Soleno Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
